{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:13:31Z","timestamp":1794287611706,"version":"4.9.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05894-4","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:43:55Z","timestamp":1746852235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A novel approach to cardiovascular events in patients with systemic lupus erythematosus: risk factor assessment and treatment analysis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-6709","authenticated-orcid":false,"given":"Dorota","family":"Suszek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0043-780X","authenticated-orcid":false,"given":"Magdalena","family":"Pop\u0142awska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8067-9503","authenticated-orcid":false,"given":"Jakub","family":"Pro\u015bniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2591-558X","authenticated-orcid":false,"given":"Katarzyna","family":"Siemieniec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6153-8359","authenticated-orcid":false,"given":"Karolina","family":"Przenios\u0142o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8882-7011","authenticated-orcid":false,"given":"Weronika","family":"Wallach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-5907","authenticated-orcid":false,"given":"Monika","family":"\u017bybowska-M\u0119czy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4098-7213","authenticated-orcid":false,"given":"Klaudia","family":"Ostrowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4553-0825","authenticated-orcid":false,"given":"Anna","family":"Rzewuska-Fija\u0142kowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3916-4291","authenticated-orcid":false,"given":"Bo\u017cena","family":"Targo\u0144ska -St\u0119pniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"issue":"2","key":"5894_CR1","doi-asserted-by":"publisher","first-page":"e22027","DOI":"10.7759\/cureus.22027","volume":"14","author":"SB Jha","year":"2022","unstructured":"Jha SB, Rivera AP, Flores Monar GV et al (2022) Systemic lupus erythematosus and cardiovascular disease. Cureus 14(2):e22027. https:\/\/doi.org\/10.7759\/cureus.22027","journal-title":"Cureus"},{"issue":"1","key":"5894_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/kead184","volume":"63","author":"N Papazoglou","year":"2024","unstructured":"Papazoglou N, Kravvariti E, Konstantonis G et al (2024) The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus. Rheumatology (Oxford) 63(1):50\u201357. https:\/\/doi.org\/10.1093\/rheumatology\/kead184","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5894_CR3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/acr.23018","volume":"69","author":"JA Avi\u00f1a-Zubieta","year":"2017","unstructured":"Avi\u00f1a-Zubieta JA, To F, Vostretsova K et al (2017) Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: A general Population-Based study. Arthritis Care Res (Hoboken) 69(6):849\u2013856. https:\/\/doi.org\/10.1002\/acr.23018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"5894_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0002-9343(76)90431-9","volume":"60","author":"MB Urowitz","year":"1976","unstructured":"Urowitz MB, Bookman AA, Koehler BE et al (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60(2):221\u2013225. https:\/\/doi.org\/10.1016\/0002-9343(76)90431-9","journal-title":"Am J Med"},{"issue":"4","key":"5894_CR5","doi-asserted-by":"publisher","first-page":"e57842","DOI":"10.7759\/cureus.57842","volume":"16","author":"Y Alammari","year":"2024","unstructured":"Alammari Y, Albednah FA, Alharbi KA et al (2024) Cardiovascular morbidity in systemic lupus erythematosus: A Single-Center retrospective study. Cureus 16(4):e57842. https:\/\/doi.org\/10.7759\/cureus.57842","journal-title":"Cureus"},{"key":"5894_CR6","doi-asserted-by":"publisher","first-page":"107466","DOI":"10.1016\/j.intimp.2021.107466","volume":"94","author":"X Lu","year":"2021","unstructured":"Lu X, Wang Y, Zhang J et al (2021) Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis. Int Immunopharmacol 94:107466. https:\/\/doi.org\/10.1016\/j.intimp.2021.107466","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"5894_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/09612033221147471","volume":"32","author":"N Bello","year":"2023","unstructured":"Bello N, Meyers KJ, Workman J et al (2023) Cardiovascular events and risk in patients with systemic lupus erythematosus: systematic literature review and meta-analysis. Lupus 32(3):325\u2013341. https:\/\/doi.org\/10.1177\/09612033221147471","journal-title":"Lupus"},{"key":"5894_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/ITT.S377076","volume":"12","author":"T Semalulu","year":"2023","unstructured":"Semalulu T, Tago A, Zhao K, Tselios K (2023) Managing cardiovascular risk in systemic lupus erythematosus: considerations for the clinician. Immunotargets Ther 12:175\u2013186. https:\/\/doi.org\/10.2147\/ITT.S377076","journal-title":"Immunotargets Ther"},{"issue":"9","key":"5894_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1191\/0961203305lu2200oa","volume":"14","author":"A Doria","year":"2005","unstructured":"Doria A, Iaccarino L, Sarzi-Puttini P et al (2005) Cardiac involvement in systemic lupus erythematosus. Lupus 14(9):683\u2013686. https:\/\/doi.org\/10.1191\/0961203305lu2200oa","journal-title":"Lupus"},{"issue":"1","key":"5894_CR10","doi-asserted-by":"publisher","first-page":"e000448","DOI":"10.1136\/lupus-2020-000448","volume":"8","author":"J Sivakumaran","year":"2021","unstructured":"Sivakumaran J, Harvey P, Omar A et al (2021) Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Sci Med 8(1):e000448. https:\/\/doi.org\/10.1136\/lupus-2020-000448","journal-title":"Lupus Sci Med"},{"issue":"1","key":"5894_CR11","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41598-024-51546-1","volume":"14","author":"JY Han","year":"2024","unstructured":"Han JY, Cho SK, Kim H et al (2024) Increased cardiovascular risk in Korean patients with systemic lupus erythematosus: a population-based cohort study. Sci Rep 14(1):1082. https:\/\/doi.org\/10.1038\/s41598-024-51546-1","journal-title":"Sci Rep"},{"key":"5894_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/CRD.0000000000000358","volume":"30","author":"NK Zagelbaum Ward","year":"2022","unstructured":"Zagelbaum Ward NK, Linares-Koloffon C, Posligua A et al (2022) Cardiac manifestations of systemic lupus erythematosus: an overview of the incidence, risk factors, diagnostic criteria, pathophysiology and treatment options. Cardiol Rev 30:38\u201343. https:\/\/doi.org\/10.1097\/CRD.0000000000000358","journal-title":"Cardiol Rev"},{"issue":"1","key":"5894_CR13","doi-asserted-by":"publisher","first-page":"e33449","DOI":"10.7759\/cureus.33449","volume":"15","author":"E Melano-Carranza","year":"2023","unstructured":"Melano-Carranza E, Zambrano-Zambrano A, Valle-Uitzil W et al (2023) Coronary artery disease in systemic lupus erythematosus. What Do Facts Say? Cureus 15(1):e33449. https:\/\/doi.org\/10.7759\/cureus.33449","journal-title":"What Do Facts Say? Cureus"},{"issue":"1","key":"5894_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3899\/jrheum.150460","volume":"43","author":"K Tselios","year":"2016","unstructured":"Tselios K, Sheane BJ, Gladman DD, Urowitz MB (2016) Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus: A systematic review. J Rheumatol 43(1):54\u201365. https:\/\/doi.org\/10.3899\/jrheum.150460","journal-title":"J Rheumatol"},{"issue":"5","key":"5894_CR15","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/annrheumdis-2019-216764","volume":"79","author":"K Tselios","year":"2020","unstructured":"Tselios K, Gladman DD, Su J, Urowitz M (2020) Impact of the new American college of cardiology\/american heart association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. Ann Rheum Dis 79(5):612\u2013617. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216764","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5894_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3899\/jrheum.181131","volume":"47","author":"G Stojan","year":"2020","unstructured":"Stojan G, Magder LS, Petri M (2020) Blood pressure variability and Age-related blood pressure patterns in systemic lupus erythematosus. J Rheumatol 47(3):387\u2013393. https:\/\/doi.org\/10.3899\/jrheum.181131","journal-title":"J Rheumatol"},{"issue":"6","key":"5894_CR17","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","volume":"81","author":"GC Drosos","year":"2022","unstructured":"Drosos GC, Vedder D, Houben E et al (2022) EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 81(6):768\u2013779. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221733","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5894_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.semarthrit.2015.10.010","volume":"45","author":"K Tselios","year":"2016","unstructured":"Tselios K, Koumaras C, Gladman DD, Urowitz MB (2016) Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum 45(5):604\u2013610. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.10.010","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"5894_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/rheumatology\/keg436","volume":"43","author":"J Wajed","year":"2004","unstructured":"Wajed J, Ahmad Y, Durrington PN, Bruce IN (2004) Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatology (Oxford) 43(1):7\u201312. https:\/\/doi.org\/10.1093\/rheumatology\/keg436","journal-title":"Rheumatology (Oxford)"},{"issue":"17","key":"5894_CR20","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.2174\/1381612811319170020","volume":"19","author":"N Katsiki","year":"2013","unstructured":"Katsiki N, Nikolic D, Montalto G et al (2013) The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 19(17):3124\u20133131. https:\/\/doi.org\/10.2174\/1381612811319170020","journal-title":"Curr Pharm Des"},{"issue":"3","key":"5894_CR21","first-page":"132","volume":"37","author":"LK Wijaya","year":"2005","unstructured":"Wijaya LK, Kasjmir YI, Sukmana N et al (2005) The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution of correlated factors. Acta Med Indones 37(3):132\u2013144","journal-title":"Acta Med Indones"},{"issue":"1","key":"5894_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5603\/RF.2023.0004","volume":"9","author":"E Kowynia","year":"2023","unstructured":"Kowynia E, Grygiel-G\u00f3rniak B, Samborski W (2023) Risk factors for lipid disorders in systemic lupus erythematosus. Rheumatol Forum 9(1):14\u201322. https:\/\/doi.org\/10.5603\/RF.2023.0004","journal-title":"Rheumatol Forum"},{"key":"5894_CR23","doi-asserted-by":"publisher","first-page":"152468","DOI":"10.1016\/j.semarthrit.2024.152468","volume":"67","author":"MY Choi","year":"2024","unstructured":"Choi MY, Guan H, Yoshida K et al (2024) Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus. Semin Arthritis Rheum 67:152468. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152468","journal-title":"Semin Arthritis Rheum"},{"key":"5894_CR24","doi-asserted-by":"publisher","unstructured":"Choe JY, Lee SS, Kwak SK, Kim SK (2020) Anti-Sm antibody, damage index, and corticosteroid use are associated with cardiac involvement in systemic lupus erythematosus: data from a prospective registry study. J Korean Med Sci 35(21). https:\/\/doi.org\/10.3346\/jkms.2020.35.e139","DOI":"10.3346\/jkms.2020.35.e139"},{"issue":"3","key":"5894_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/eurjpc\/zwaa256","volume":"28","author":"GC Drosos","year":"2020","unstructured":"Drosos GC, Konstantonis G, Sfikakis PP, Tektonidou MG (2020) Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. Eur J Prev Cardiol 28(3):346\u2013352. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa256","journal-title":"Eur J Prev Cardiol"},{"issue":"25 Pt B","key":"5894_CR26","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G et al (2014) 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology\/american heart association task force on practice guidelines. J Am Coll Cardiol 63(25 Pt B):2935\u20132959. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.005","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"5894_CR27","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1002\/art.11296","volume":"48","author":"IN Bruce","year":"2003","unstructured":"Bruce IN, Urowitz MB, Gladman DD, Iba\u00f1ez D et al (2003) Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto risk factor study. Arthritis Rheum 48(11):3159\u20133316. https:\/\/doi.org\/10.1002\/art.11296","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5894_CR28","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3899\/jrheum.150983","volume":"43","author":"MB Urowitz","year":"2016","unstructured":"Urowitz MB, Iba\u00f1ez D, Su J, Gladman DD (2016) Modified Framingham risk factor score for systemic lupus erythematosus. J Rheumatol 43(5):875\u2013879. https:\/\/doi.org\/10.3899\/jrheum.150983","journal-title":"J Rheumatol"},{"issue":"1","key":"5894_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/art.38204","volume":"66","author":"M McMahon","year":"2014","unstructured":"McMahon M, Skaggs BJ, Grossman JM et al (2014) A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol 66(1):130\u2013139. https:\/\/doi.org\/10.1002\/art.38204","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"5894_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/acr2.11223","volume":"3","author":"BJ Skaggs","year":"2021","unstructured":"Skaggs BJ, Grossman J, Sahakian L et al (2021) A panel of biomarkers associates with increased risk for cardiovascular events in women with systemic lupus erythematosus. ACR Open Rheumatol 3(4):209\u2013220. https:\/\/doi.org\/10.1002\/acr2.11223","journal-title":"ACR Open Rheumatol"},{"key":"5894_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/rheumatology\/kep037","volume":"48","author":"SG O\u2019Neill","year":"2009","unstructured":"O\u2019Neill SG, Pego JM, Hingorani AD et al (2009) Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 48:573\u2013575. https:\/\/doi.org\/10.1093\/rheumatology\/kep037","journal-title":"Rheumatology (Oxford)"},{"key":"5894_CR32","doi-asserted-by":"publisher","first-page":"357j2099","DOI":"10.1136\/bmj.j2099","volume":"23","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P (2017) Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 23:357j2099. https:\/\/doi.org\/10.1136\/bmj.j2099","journal-title":"BMJ"},{"issue":"1","key":"5894_CR33","doi-asserted-by":"publisher","first-page":"e000564","DOI":"10.1136\/lupus-2021-000564","volume":"9","author":"L Zhu","year":"2022","unstructured":"Zhu L, Singh M, Lele S et al (2022) Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus. Lupus Sci Med 9(1):e000564. https:\/\/doi.org\/10.1136\/lupus-2021-000564","journal-title":"Lupus Sci Med"},{"key":"5894_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijcard.2022.06.040","volume":"363","author":"A Barinotti","year":"2022","unstructured":"Barinotti A, Radin M, Cecchi I et al (2022) Assessing the cardiovascular risk in patients with systemic lupus erythematosus: QRISK and GAPSS scores head-to-head. Int J Cardiol 363:185\u2013189. https:\/\/doi.org\/10.1016\/j.ijcard.2022.06.040","journal-title":"Int J Cardiol"},{"issue":"5","key":"5894_CR35","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/BOR.0000000000000307","volume":"28","author":"LB Lewandowski","year":"2016","unstructured":"Lewandowski LB, Kaplan MJ (2016) Update on cardiovascular disease in lupus. Curr Opin Rheumatol 28(5):468\u2013476. https:\/\/doi.org\/10.1097\/BOR.0000000000000307","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"5894_CR36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","volume":"49","author":"M Radin","year":"2019","unstructured":"Radin M, Sciascia S, Erkan D et al (2019) The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. Semin Arthritis Rheum 49(3):464\u2013468. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.04.009","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"5894_CR37","doi-asserted-by":"publisher","first-page":"e000864","DOI":"10.1136\/lupus-2022-000864","volume":"10","author":"S Panopoulos","year":"2023","unstructured":"Panopoulos S, Drosos GC, Konstantonis G et al (2023) Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE. Lupus Sci Med 10(1):e000864. https:\/\/doi.org\/10.1136\/lupus-2022-000864","journal-title":"Lupus Sci Med"},{"key":"5894_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2018.09.010","volume":"278","author":"MND Di Minno","year":"2018","unstructured":"Di Minno MND, Scalera A, Tufano A et al (2018) The association of adjusted global antiphospholipid syndrome score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies. Atherosclerosis 278:60\u201365. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.09.010","journal-title":"Atherosclerosis"},{"key":"5894_CR39","doi-asserted-by":"publisher","first-page":"1759720X2210923","DOI":"10.1177\/1759720X221092373","volume":"19","author":"JC Quevedo-Abeledo","year":"2022","unstructured":"Quevedo-Abeledo JC, Gonz\u00e1lez-Gay M\u00c1, Ferraz-Amaro I (2022) SCORE2 versus SCORE in patients with systemic lupus erythematosus. Ther Adv Musculoskelet Dis 19:14:1759720X221092373. https:\/\/doi.org\/10.1177\/1759720X221092373","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"5894_CR40","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1038\/s41598-017-07574-1","volume":"4","author":"A Mak","year":"2017","unstructured":"Mak A, Kow NY, Schwarz H et al (2017) Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression. Sci Rep 4(1):7320. https:\/\/doi.org\/10.1038\/s41598-017-07574-1","journal-title":"Sci Rep"},{"issue":"6","key":"5894_CR41","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s10753-014-9940-z","volume":"37","author":"DG Wang","year":"2014","unstructured":"Wang DG, Tang XW, Fan Y et al (2014) Decreased flow-mediated dilatation in patients with systemic lupus erythematosus: a meta-analysis. Inflammation 37(6):2067\u20132075. https:\/\/doi.org\/10.1007\/s10753-014-9940-z","journal-title":"Inflammation"},{"key":"5894_CR42","doi-asserted-by":"publisher","first-page":"102863","DOI":"10.1016\/j.jaut.2022.102863","volume":"132","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yu X, Zhang W et al (2022) Mechanistic insight into premature atherosclerosis and cardiovascular complications in systemic lupus erythematosus. J Autoimmun 132:102863. https:\/\/doi.org\/10.1016\/j.jaut.2022.102863","journal-title":"J Autoimmun"},{"issue":"3","key":"5894_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/0003319717715964","volume":"69","author":"P Wang","year":"2018","unstructured":"Wang P, Mao YM, Zhao CN et al (2018) Increased pulse wave velocity in systemic lupus erythematosus: a Meta-Analysis. Angiology 69(3):228\u2013235. https:\/\/doi.org\/10.1177\/0003319717715964","journal-title":"Angiology"},{"issue":"11","key":"5894_CR44","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1191\/0961203305lu2234oa","volume":"14","author":"TK Tso","year":"2005","unstructured":"Tso TK, Huang WN, Huang HY, Chang CK (2005) Association of brachial-ankle pulse wave velocity with cardiovascular risk factors in systemic lupus erythematosus. Lupus 14(11):878\u2013883. https:\/\/doi.org\/10.1191\/0961203305lu2234oa","journal-title":"Lupus"},{"issue":"7","key":"5894_CR45","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.3390\/jcm13071988","volume":"29","author":"FI Corona-Meraz","year":"2024","unstructured":"Corona-Meraz FI, V\u00e1zquez-Del Mercado M, Sandoval-Garc\u00eda F et al (2024) Biomarkers in systemic lupus erythematosus along with metabolic syndrome. J Clin Med 29(7):1988. https:\/\/doi.org\/10.3390\/jcm13071988","journal-title":"J Clin Med"},{"key":"5894_CR46","unstructured":"Shoenfeld Y (2017) The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic Approaches, 1st edition. Isr Med Assoc J.;19(6):395\u2013396"},{"key":"5894_CR47","doi-asserted-by":"publisher","first-page":"20207025329","DOI":"10.1155\/2020\/7025329","volume":"5","author":"B Przywara-Chowaniec","year":"2020","unstructured":"Przywara-Chowaniec B, Blachut D, Harpula J et al (2020) Systemic lupus erythematosus, its impact on selected cardiovascular risk factors, and correlation with duration of illness: A pilot study. Cardiol Res Pract 5:20207025329. https:\/\/doi.org\/10.1155\/2020\/7025329","journal-title":"Cardiol Res Pract"},{"issue":"11","key":"5894_CR48","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1093\/rheumatology\/kev198","volume":"54","author":"AN Kiani","year":"2015","unstructured":"Kiani AN, Magder LS, Post WS et al (2015) Coronary calcification in SLE: comparison with the Multi-Ethnic study of atherosclerosis. Rheumatology 54(11):1976\u20131981. https:\/\/doi.org\/10.1093\/rheumatology\/kev198","journal-title":"Rheumatology"},{"issue":"1","key":"5894_CR49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00296-016-3615-z","volume":"37","author":"A Khan","year":"2017","unstructured":"Khan A, Arbab-Zadeh A, Kiani AN et al (2017) Progression of noncalcified and calcified coronary plaque by CT angiography in SLE. Rheumatol Int 37(1):59\u201365. https:\/\/doi.org\/10.1007\/s00296-016-3615-z","journal-title":"Rheumatol Int"},{"issue":"3","key":"5894_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/0961203310381512","volume":"20","author":"M Nikpour","year":"2011","unstructured":"Nikpour M, Urowitz M, Iba\u00f1ez D, Gladman D (2011) Relationship between cardiac symptoms, myocardial perfusion defects and coronary angiography findings in systemic lupus erythematosus. Lupus 20(3):299\u2013304. https:\/\/doi.org\/10.1177\/0961203310381512","journal-title":"Lupus"},{"issue":"2","key":"5894_CR51","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/acr.21782","volume":"65","author":"MS Kaul","year":"2013","unstructured":"Kaul MS, Rao SV, Shaw LK et al (2013) Association of systemic lupus erythematosus with angiographically defined coronary artery disease: a retrospective cohort study. Arthritis Care Res 65(2):266\u2013273. https:\/\/doi.org\/10.1002\/acr.21782","journal-title":"Arthritis Care Res"},{"issue":"10","key":"5894_CR52","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00011-011-0358-x","volume":"60","author":"W Plazak","year":"2011","unstructured":"Plazak W, Pasowicz M, Kostkiewicz M et al (2011) Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients. Inflamm Res 60(10):973\u2013980. https:\/\/doi.org\/10.1007\/s00011-011-0358-x","journal-title":"Inflamm Res"},{"issue":"15","key":"5894_CR53","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.113.002744","volume":"128","author":"R Doukky","year":"2013","unstructured":"Doukky R, Hayes K, Frogge N et al (2013) Impact of appropriate use on the prognostic value of single-photon emission computed tomography myocardial perfusion imaging. Circulation 128(15):1634\u20131643. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.002744","journal-title":"Circulation"},{"issue":"10","key":"5894_CR54","doi-asserted-by":"publisher","first-page":"e0202105","DOI":"10.1371\/journal.pone.0202105","volume":"13","author":"T Burkard","year":"2018","unstructured":"Burkard T, Trendelenburg M, Daikeler T et al (2018) The heart in systemic lupus erythematosus\u2013 A comprehensive approach by cardiovascular magnetic resonance tomography. PLoS ONE 13(10):e0202105. https:\/\/doi.org\/10.1371\/journal.pone.0202105","journal-title":"PLoS ONE"},{"issue":"1","key":"5894_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/acr.22181","volume":"66","author":"S Mavrogeni","year":"2014","unstructured":"Mavrogeni S, Sfikakis PP, Gialafos E et al (2014) Cardiac tissue characterization and the diagnostic value of cardiovascular magnetic resonance in systemic connective tissue diseases. Arthritis Care Res 66(1):104\u2013112. https:\/\/doi.org\/10.1002\/acr.22181","journal-title":"Arthritis Care Res"},{"issue":"6","key":"5894_CR56","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K et al (2019) Update of the joint European league against rheumatism and European renal association-European Dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79(6):713\u2013723. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216924","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5894_CR57","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/acr.20393","volume":"63","author":"SJ Morris","year":"2011","unstructured":"Morris SJ, Wasko MC, Antohe JL et al (2011) Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 63(4):530\u2013534. https:\/\/doi.org\/10.1002\/acr.20393","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"5894_CR58","first-page":"780","volume":"28","author":"EF Borba","year":"2001","unstructured":"Borba EF, Bonf\u00e1 E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28(4):780\u2013785","journal-title":"J Rheumatol"},{"key":"5894_CR59","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/annrheumdis-2012-eular.3169","volume":"71","author":"G Law","year":"2013","unstructured":"Law G, Magder L, Fang H, Petri M (2013) SAT0222 hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, particularly in antiphospholipid positive patients. Ann Rheum Dis 71:547\u2013547. https:\/\/doi.org\/10.1136\/annrheumdis-2012-eular.3169","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5894_CR60","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/ard.2008.093013","volume":"68","author":"R Kaiser","year":"2009","unstructured":"Kaiser R, Cleveland CM, Criswell LA (2009) Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 68(2):238\u2013241. https:\/\/doi.org\/10.1136\/ard.2008.093013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5894_CR61","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0961203307086503","volume":"17","author":"A Sis\u00f3","year":"2008","unstructured":"Sis\u00f3 A, Ramos-Casals M, Bov\u00e9 A et al (2008) Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 17(4):281\u2013288. https:\/\/doi.org\/10.1177\/0961203307086503","journal-title":"Lupus"},{"key":"5894_CR62","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2147\/DDDT.S166893","volume":"12","author":"D Liu","year":"2018","unstructured":"Liu D, Li X, Zhang Y et al (2018) Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Des Devel Ther 12:1685\u20131695. https:\/\/doi.org\/10.2147\/DDDT.S166893","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"5894_CR63","doi-asserted-by":"publisher","first-page":"16656","DOI":"10.20452\/pamw.16656","volume":"134","author":"K Pawlak-Bu\u015b","year":"2024","unstructured":"Pawlak-Bu\u015b K, Leszczy\u0144ski P (2024) Hydroxychloroquine as an important Immunomodulator: a novel insight into an old drug. Pol Arch Intern Med 134(1):16656. https:\/\/doi.org\/10.20452\/pamw.16656","journal-title":"Pol Arch Intern Med"},{"key":"5894_CR64","unstructured":"Stokkermans TJ, Falkowitz DM, Trichonas G (2024) Chloroquine and Hydroxychloroquine Toxicity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan 11. Bookshelf ID: NBK537086"},{"key":"5894_CR65","doi-asserted-by":"publisher","unstructured":"Brouqui P, Chabriere E, Raoult D (2024) Hydroxychloroquine: pharmacokinetics and toxicity. Journal of clinical pharmacy and therapeutics (RR-03). 1\u201312. https:\/\/doi.org\/10.1155\/2024\/6500340","DOI":"10.1155\/2024\/6500340"},{"issue":"1","key":"5894_CR66","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.atherosclerosis.2010.01.043","volume":"211","author":"SI van Leuven","year":"2010","unstructured":"73, van Leuven SI, van Wijk DF, Volger OL et al (2010) Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 211(1):231\u2013236. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.01.043","journal-title":"Atherosclerosis"},{"issue":"3","key":"5894_CR67","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/annrheumdis-2011-200071","volume":"71","author":"SI van Leuven","year":"2012","unstructured":"van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ et al (2012) Mycophenolate mofetil but not Atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-\/-) mice. Ann Rheum Dis 71(3):408\u2013414. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200071","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5894_CR68","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00296-011-2048-y","volume":"32","author":"AN Kiani","year":"2012","unstructured":"Kiani AN, Magder LS, Petri M (2012) Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol Int 32(9):2701\u20132705. https:\/\/doi.org\/10.1007\/s00296-011-2048-y","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05894-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05894-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05894-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T09:30:09Z","timestamp":1750239009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05894-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":68,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["5894"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05894-4","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No part of this review has been copied or published elsewhere in whole or in part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Authors: Dorota Suszek, Magdalena Pop\u0142awska, Jakub Pro\u015bniak, Katarzyna Siemieniec, Karolina Przenios\u0142o, Weronika Wallach, Monika \u017bybowska-M\u0119czy\u0144ska, Klaudia Ostrowicz, Anna Rzewuska-Fija\u0142kowska, Bo\u017cena Targo\u0144ska - St\u0119pniak declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"139"}}